左炔诺孕酮治疗子宫内膜增生症的效果及作用机制研究
|
摘要
目的分析左炔诺孕酮治疗子宫内膜增生症的临床有效性与作用机制。方法收集子宫内膜增生症患者156例,随机分为2组,每组78例。试验组给予左炔诺孕酮宫内缓释系统治疗,对照组给予醋酸甲羟孕酮口服治疗,比较2组患者治疗效果。观察2组治疗后月经评分、子宫内膜厚度,采用免疫组化方法检测雌、孕激素受体含量变化情况。结果治疗后2组患者经量及子宫内膜厚度均改善,其中试验组改善明显,差异有统计学意义(P<0.05);与对照组比较,试验组患者子宫内膜腺体、间质中雌激素受体、孕激素受体含量较低,差异有统计学意义(P<0.05)。结论左炔诺孕酮宫内缓释系统对子宫内膜增生症患者治疗效果显著,能有效改善患者月经紊乱及子宫内膜厚度,具有较好的临床应用价值及意义。
Objective To investigate the clinical efficacy and action mechanism of levonorgestrel in treatment of endometrial hyperplasia.Methods A total of 156 patients with endometrial hyperplasia were randomly divided into experimental group and control group,with 78 cases in each group.The patients in control group were treated by oral medroxyprogesterone acetate tablets,however,the patients in experimental group were treated by levonorgestrel intrauterine delivery system.After treatment the clinical efficacy,menstrual score and endometrial thickness were observed and compared between the two groups. Moreover the changes of estrogen and progesterone receptor levels were detected by immunohistochemistry.Results After treatment,the menstrual volume and endometrial thickness were improved in both groups,and the improvement degree in experimental group was more significant than that in control group(P<0.05).In addition the levels of endometrial gland,interstitial estrogen receptor,progesterone receptor in experimental group were significantly lower than those in control group(P<0.05). Conclusion The application of levonorgestrel intrauterine delivery system in treatment of endometrial hyperplasia can obtain obvious therapeutic effects,which can improve the menstrual disorder and endometrial thickness of patients,therefor,it is worthy of clinical application and promotion.
Objective To investigate the clinical efficacy and action mechanism of levonorgestrel in treatment of endometrial hyperplasia.Methods A total of 156 patients with endometrial hyperplasia were randomly divided into experimental group and control group,with 78 cases in each group.The patients in control group were treated by oral medroxyprogesterone acetate tablets,however,the patients in experimental group were treated by levonorgestrel intrauterine delivery system.After treatment the clinical efficacy,menstrual score and endometrial thickness were observed and compared between the two groups. Moreover the changes of estrogen and progesterone receptor levels were detected by immunohistochemistry.Results After treatment,the menstrual volume and endometrial thickness were improved in both groups,and the improvement degree in experimental group was more significant than that in control group(P<0.05).In addition the levels of endometrial gland,interstitial estrogen receptor,progesterone receptor in experimental group were significantly lower than those in control group(P<0.05). Conclusion The application of levonorgestrel intrauterine delivery system in treatment of endometrial hyperplasia can obtain obvious therapeutic effects,which can improve the menstrual disorder and endometrial thickness of patients,therefor,it is worthy of clinical application and promotion.
引文
1 全桂凤.左炔诺孕酮宫内缓释系统治疗子宫内膜增生症的疗效观察.临床医药文献电子杂志,2016,3:11240-11241.
2 王慧,郭秀玲.子宫内膜增生症中不同因素及治疗方法与临床效果的相关性研究.泰山医学院学报,2018,39:136-138.
3 翟芬菊,李彩菊,杨利.子宫内膜增生相关因素分析.中国妇幼保健,2012,27:2455-2456.
4 谢敏,王悦,王建六.子宫内膜异常增生74例相关因素分析.中国医药指南,2010,8:67-68.
5 Ellenson LH.Blaustein’s pathology of the female genital tract.New York:Springer,2011.360.
6 李武志.子宫内膜增生症的诊治进展.中华妇幼临床医学杂志,2017,13:244-248.
7 陈少娟.左炔诺孕酮宫内缓释器在子宫内膜增生治疗中的作用研究.中国继续医学教育,2018,10:117-118.
8 朱云霞.左炔诺孕酮宫内缓释系统在子宫内膜增生症患者治疗中的作用分析.中国医药科学,2013,3:158-159.
9 Committee on Gynecologic Practice.Society of Gynecologic Oncology.The American College of Obstetricians and Gynecologists Committee Opinion No.631.Obstet Gynecol,2015,125:1272-1278.
10 Royal College of Obstetricians and Gynecologists Management of endometrial hyperplasia.Green-top guideline No.67 RCOG/BSGE joint guideline.London:RCOG Press,2016.
11 Andrade A,Wildemeersch D.Menstrual blood loss in women using the frameless fibro plant LNG-IUS.Contraception,2009,79:134.
12 周敏,张呈艳,朱彩芳,等.左炔诺孕酮宫内缓释系统治疗子宫内膜增生的临床疗效及对患者性激素和性激素受体水平的影响.中国妇幼保健,2017,32:1771-1773.
13 Abu Hashim H,Zayed A,Ghayaty E,et al.LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women:a randomized controlled trial.J Gynecol Oncol,2013,24:128-134.
14 张敏.左炔诺孕酮宫内缓释系统及孕激素治疗子宫内膜增生症的对照观察.中外女性健康研究,2018,7:36-37.
15 李晓燕,冷金花.左炔诺孕酮宫内缓释系统(曼月乐环)治疗子宫内膜增生的临床疗效分析.生殖医学杂志,2017,26:336-340.
16 蒋智.左炔诺孕酮宫内缓释系统治疗功能性子宫出血及子宫内膜增生过长72例.中国药业,2015,24:97-99.
2 王慧,郭秀玲.子宫内膜增生症中不同因素及治疗方法与临床效果的相关性研究.泰山医学院学报,2018,39:136-138.
3 翟芬菊,李彩菊,杨利.子宫内膜增生相关因素分析.中国妇幼保健,2012,27:2455-2456.
4 谢敏,王悦,王建六.子宫内膜异常增生74例相关因素分析.中国医药指南,2010,8:67-68.
5 Ellenson LH.Blaustein’s pathology of the female genital tract.New York:Springer,2011.360.
6 李武志.子宫内膜增生症的诊治进展.中华妇幼临床医学杂志,2017,13:244-248.
7 陈少娟.左炔诺孕酮宫内缓释器在子宫内膜增生治疗中的作用研究.中国继续医学教育,2018,10:117-118.
8 朱云霞.左炔诺孕酮宫内缓释系统在子宫内膜增生症患者治疗中的作用分析.中国医药科学,2013,3:158-159.
9 Committee on Gynecologic Practice.Society of Gynecologic Oncology.The American College of Obstetricians and Gynecologists Committee Opinion No.631.Obstet Gynecol,2015,125:1272-1278.
10 Royal College of Obstetricians and Gynecologists Management of endometrial hyperplasia.Green-top guideline No.67 RCOG/BSGE joint guideline.London:RCOG Press,2016.
11 Andrade A,Wildemeersch D.Menstrual blood loss in women using the frameless fibro plant LNG-IUS.Contraception,2009,79:134.
12 周敏,张呈艳,朱彩芳,等.左炔诺孕酮宫内缓释系统治疗子宫内膜增生的临床疗效及对患者性激素和性激素受体水平的影响.中国妇幼保健,2017,32:1771-1773.
13 Abu Hashim H,Zayed A,Ghayaty E,et al.LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women:a randomized controlled trial.J Gynecol Oncol,2013,24:128-134.
14 张敏.左炔诺孕酮宫内缓释系统及孕激素治疗子宫内膜增生症的对照观察.中外女性健康研究,2018,7:36-37.
15 李晓燕,冷金花.左炔诺孕酮宫内缓释系统(曼月乐环)治疗子宫内膜增生的临床疗效分析.生殖医学杂志,2017,26:336-340.
16 蒋智.左炔诺孕酮宫内缓释系统治疗功能性子宫出血及子宫内膜增生过长72例.中国药业,2015,24:97-99.